Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21-70
SponsorSingapore General Hospital
About this trial
The purpose of this research study is to determine whether taking glycine, a naturally occurring amino acid, as a supplement improves liver health measurements in individuals with Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD).
This project will be divided into two parts. The first part will be a case-control study comparing parameters of glycine-dependent metabolic pathways between individuals with MASLD and healthy controls. The second part will be a randomized placebo-controlled trial (RCT) to evaluate the impact of 26-week dietary glycine supplementation on parameters of liver health versus 26-week placebo in patients with MASLD.
Eligibility criteria
Qualifiers
Age 21-70 years
Ability to provide informed consent.
Hepatic steatosis on MRI
BMI of 25-50 kg/m2
Disqualifiers
Uncontrolled diabetes (HbA1c > 8%)
Type 1 Diabetes Mellitus
Clinically significant anemia (Haemoglobin < 10 g/dL)
Chronic liver disorders (except MASLD) such as Hepatitis B, Hepatitis C, Wilson's disease, hemochromatosis, autoimmune hepatitis, chronic cholestatic disorders, and liver cirrhosis
Trial design
Treatments tested in this trial
- Glycine
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov